Brenda Marshall, MD

Sydnexis Inc., based in Del Mar, CA, is dedicated to addressing the critical innovation gap in pediatric progressive myopia (PPM), a leading cause of vision loss in children. The company is committed to advancing pharmaceutical solutions that aim to slow the progression of myopia, especially in younger patients, to help preserve their vision for life. With a focus on scientific research, Sydnexis is developing low-dose atropine eye drops specifically engineered for children, backed by the landmark STAR study, which provides rigorous long-term data. As the first and only pharmaceutical treatment approved in the European Union for this purpose, Sydnexis is poised to make a significant impact on pediatric ophthalmology. Generated from the website